Glycosylated Hemoglobin and Risk of Perioperative Major Cardiovascular Events in Diabetic Patients Undergoing Coronary Bypass Revascularization (HbA1c)

University Hospital, Basel, Switzerland589 enrolled

Overview

Glycosylated Hemoglobin (HbA1c) is considered as one of the best markers to assess the glycaemia treatment over a period of 3 to 4 months, and is considered as predictive marker for perioperative mortality and morbidity. The impact of the elevated HbA1c on the risk of perioperative major cardiovascular events in patients undergoing coronary bypass revascularization (by retrospective analysis of perioperative cardiovascular events and preoperative HbA1c) is evaluated.

Study Type

OBSERVATIONAL

Enrollment

589

Conditions

Cardiovascular Event Coronary Artery Bypass Graft Diabetes Mellitus

Interventions

Coronary Bypass RevascularizationPROCEDURE

analysis of perioperative major cardiovascular events in diabetic patients

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * patients with Diabetes mellitus undergoing coronary bypass revascularization since 2012 Exclusion Criteria: * disapproval of use of data for research purposes

Locations (1)

Herzchirurgie University Hospital Basel

Basel, Switzerland

Outcomes

Primary Outcomes

occurence of Major adverse cardiac events

myocardial infarction, cardiac related death, stroke

Time frame: perioperative = in hospital

Secondary Outcomes

occurence of severe renal insufficiency

application of renal replacement therapy (renal dialysis)

Time frame: perioperative = in hospital

occurence of sternal wound infection

sternal wound infection

Time frame: perioperative = in hospital

mortality

death rate perioperative

Time frame: perioperative = in hospital

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.